to 24 months post-Sculptra injection and outcome ranged from ‘recovered’ to ‘ongoing’
at last contact.
Skin discoloration was reported as a non-serious event, typically reported in association
with lumps and nodules. It has also been reported with blanching and telangiectasias.
Time to onset when specified usually ranged from within 1 week to 12 months post-
injection. Outcome ranged from ‘recovered’ to ‘ongoing’ at last contact.
Serious adverse events have rarely been reported. The most commonly reported serious
adverse events for Sculptra with more than 5 reported events include papule/nodule,
swelling/edema, pain, granuloma, symptoms of visual disturbance, infection/abscess,
mass/induration, paresthesia and facial nerve paralysis, erythema, inflammation,
bruising/hematoma, discoloration, deformity, scaring/atrophy, hypersensitivity, pruritus,
rash, muscle disorders, ischemia/necrosis, urticaria and blisters.
Injection site nodules mostly occurred several months post-injection. Such nodules are
occasionally associated with inflammation or discoloration, with time to onset ranging
from 1-2 months to 14 months post-last injection. In some cases, the nodules were
reported to resolve spontaneously or following treatment with, e.g. intralesional
corticosteroids, others were described with a prolonged duration of up to 2 years. For
those nodules that were larger in size, occurring in difficult anatomical regions (e.g.
lower eyelid) or persisted after other treatments such as intralesional corticosteroids
failed, surgical excision of the nodules was required.
Granulomas usually occur several months after injection; in few cases onset was more
than 1-year post-injection. While events were reported as granuloma, only a few cases
were confirmed by biopsy. Treatment ranged from subcision or intralesional
corticosteroid with subsequent improvement, to surgical extraction. Of the few
granuloma cases that required hospitalization, these were associated with infraorbital use
or injection in the lip vermilion.
Vascular compromise may occur due to an inadvertent intravascular injection or as a
result of vascular compression associated with implantation of any injectable product.
This may manifest as blanching, discoloration, necrosis or ulceration at the implant site
or in the area supplied by the blood vessels affected; or rarely as ischemic events in other
organs due to embolization. Isolated rare cases of ischemic events affecting the eye
leading to visual loss, and the brain resulting in cerebral infarction, following facial
aesthetic treatments have been reported. Visual disturbances including blindness have
been reported following injection of Sculptra into the temple area, periorbital areas,
PMA P030050/S039: FDA Summary of Safety and Effectiveness Data 6 of 40